RHYTHM PHARMACEUTICALS, INC. Unrealized Gain (Loss) on Investments
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Unrealized Gain (Loss) on Investments of $244.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2024-05-07
- RHYTHM PHARMACEUTICALS, INC. unrealized gain (loss) on investments for the quarter ending 2024-03-31 was $244.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month |
|---|---|---|
| 2024-03-31 | $244.00K 10-Q · filed 2024-05-07 | |
| 2023-06-30 | -$105.00K 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |